Home › Tricuspid Valve Insufficiency › NCT06833476

TTVR STRONG Under Coverage With Evidence Development (CED) Study

Transcatheter Tricuspid Valve Replacement (TTVR) in Patients With Severe TR ONgoing Evidence Generation (STRONG) Under Coverage With Evidence Development (CED)

Who can join

Ages 65 and older · All sexes

Inclusion Criteria:

Medicare eligible patients who have received an EVOQUE device or are EVOQUE eligible and have at least severe Tricuspid Regurgitation

Exclusion Criteria:

Commercially insured patients who have received an EVOQUE device or are EVOQUE eligible or Medicare eligible patients with less than severe Tricuspid Regurgitation

About the study

This Coverage with Evidence Development (CED) study measures the long-term health outcomes of patients with severe, symptomatic Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Replacement procedure using the EVOQUE system.

What is being tested

• EVOQUE (other)

Sponsor: Edwards Lifesciences · Participants: 2,044 · Started: Mar 19, 2025

Contact the study team

• TMTT GHER · Phone: 949-250-3849

Official record on ClinicalTrials.gov — NCT06833476

Locations in the U.S.

Conditions

• Tricuspid Valve Insufficiency

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.